Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: A pilot study

Pier Giorgio Crosignani, Luigi De Cecco, Attilio Gastaldi, Pier Luigi Venturini, Sabina Oldani, Walter Vegetti, Antonio Sémino, Paolo La Commare, Paolo Vercellini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

An open-label randomized pilot study was conducted to evaluate the efficacy and acceptability of 6 months treatment with leuprolide in a 3-monthly versus a monthly i.m. depot injection for the relief of chronic pelvic pain in women with endometriosis. A total of 30 women aged 18-38 years were allocated to the 3-monthly depot arm (n = 15) or to the monthly depot arm (n = 15) after laparoscopic diagnosis of pelvic endometriosis. Mean (SD) deep dyspareunia scores according to a 0-3 point verbal rating scale decreased from 1.8 (0.9) at baseline to 1.3 (0.7) at the end of treatment in the 3-monthly depot group and from 2.1 (1.2) to 1.3 (0.7) in the monthly depot group. Corresponding values in non-menstrual pain scores fell from 2.1 (0.6) to 1.1 (0.3), and from 2.1 (0.8) to 1.2 (0.4) respectively, without statistically significant differences between the groups. Serum luteinizing hormone (LH) and 17β-oestradiol concentrations were significantly suppressed at 12 and 24 weeks compared with baseline values, without differences between the groups. The monthly depot caused a slightly more marked inhibition of serum follicle stimulating hormone (FSH) levels with respect to the 3-monthly preparation. Mean (SD) endometriosis scores at baseline and at 6 month follow-up laparoscopy were respectively 32.8 (25.1) and 12.2 (9.3) in the 3-monthly depot group and 29.0 (22.7) acid 13.1 (15.3) in the monthly depot group (paired t-test, P <0.05). Mean percentage decrease in lumbar spine bone mineral density was 5.2% in the former and 4.9% in the latter subjects. In the 3-monthly depot group, 13 women graded the tolerability of their treatment schedule as 'good' compared with seven in the monthly depot group (χ 2 = 5.40, P = 0.02).

Original languageEnglish
Pages (from-to)2732-2735
Number of pages4
JournalHuman Reproduction
Volume11
Issue number12
Publication statusPublished - Dec 1996

Fingerprint

Leuprolide
Endometriosis
Dyspareunia
Pelvic Pain
Follicle Stimulating Hormone
Luteinizing Hormone
Serum
Chronic Pain
Bone Density
Laparoscopy
Estradiol
Appointments and Schedules
Spine
Therapeutics
Pain
Injections
Acids

Keywords

  • Endometriosis
  • Gonadotrophin releasing hormone agonists
  • Pelvic pain

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Crosignani, P. G., De Cecco, L., Gastaldi, A., Venturini, P. L., Oldani, S., Vegetti, W., ... Vercellini, P. (1996). Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: A pilot study. Human Reproduction, 11(12), 2732-2735.

Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis : A pilot study. / Crosignani, Pier Giorgio; De Cecco, Luigi; Gastaldi, Attilio; Venturini, Pier Luigi; Oldani, Sabina; Vegetti, Walter; Sémino, Antonio; La Commare, Paolo; Vercellini, Paolo.

In: Human Reproduction, Vol. 11, No. 12, 12.1996, p. 2732-2735.

Research output: Contribution to journalArticle

Crosignani, PG, De Cecco, L, Gastaldi, A, Venturini, PL, Oldani, S, Vegetti, W, Sémino, A, La Commare, P & Vercellini, P 1996, 'Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: A pilot study', Human Reproduction, vol. 11, no. 12, pp. 2732-2735.
Crosignani PG, De Cecco L, Gastaldi A, Venturini PL, Oldani S, Vegetti W et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: A pilot study. Human Reproduction. 1996 Dec;11(12):2732-2735.
Crosignani, Pier Giorgio ; De Cecco, Luigi ; Gastaldi, Attilio ; Venturini, Pier Luigi ; Oldani, Sabina ; Vegetti, Walter ; Sémino, Antonio ; La Commare, Paolo ; Vercellini, Paolo. / Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis : A pilot study. In: Human Reproduction. 1996 ; Vol. 11, No. 12. pp. 2732-2735.
@article{bb9e1469f02c4360ba92b2f3f1a1bab9,
title = "Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: A pilot study",
abstract = "An open-label randomized pilot study was conducted to evaluate the efficacy and acceptability of 6 months treatment with leuprolide in a 3-monthly versus a monthly i.m. depot injection for the relief of chronic pelvic pain in women with endometriosis. A total of 30 women aged 18-38 years were allocated to the 3-monthly depot arm (n = 15) or to the monthly depot arm (n = 15) after laparoscopic diagnosis of pelvic endometriosis. Mean (SD) deep dyspareunia scores according to a 0-3 point verbal rating scale decreased from 1.8 (0.9) at baseline to 1.3 (0.7) at the end of treatment in the 3-monthly depot group and from 2.1 (1.2) to 1.3 (0.7) in the monthly depot group. Corresponding values in non-menstrual pain scores fell from 2.1 (0.6) to 1.1 (0.3), and from 2.1 (0.8) to 1.2 (0.4) respectively, without statistically significant differences between the groups. Serum luteinizing hormone (LH) and 17β-oestradiol concentrations were significantly suppressed at 12 and 24 weeks compared with baseline values, without differences between the groups. The monthly depot caused a slightly more marked inhibition of serum follicle stimulating hormone (FSH) levels with respect to the 3-monthly preparation. Mean (SD) endometriosis scores at baseline and at 6 month follow-up laparoscopy were respectively 32.8 (25.1) and 12.2 (9.3) in the 3-monthly depot group and 29.0 (22.7) acid 13.1 (15.3) in the monthly depot group (paired t-test, P <0.05). Mean percentage decrease in lumbar spine bone mineral density was 5.2{\%} in the former and 4.9{\%} in the latter subjects. In the 3-monthly depot group, 13 women graded the tolerability of their treatment schedule as 'good' compared with seven in the monthly depot group (χ 2 = 5.40, P = 0.02).",
keywords = "Endometriosis, Gonadotrophin releasing hormone agonists, Pelvic pain",
author = "Crosignani, {Pier Giorgio} and {De Cecco}, Luigi and Attilio Gastaldi and Venturini, {Pier Luigi} and Sabina Oldani and Walter Vegetti and Antonio S{\'e}mino and {La Commare}, Paolo and Paolo Vercellini",
year = "1996",
month = "12",
language = "English",
volume = "11",
pages = "2732--2735",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis

T2 - A pilot study

AU - Crosignani, Pier Giorgio

AU - De Cecco, Luigi

AU - Gastaldi, Attilio

AU - Venturini, Pier Luigi

AU - Oldani, Sabina

AU - Vegetti, Walter

AU - Sémino, Antonio

AU - La Commare, Paolo

AU - Vercellini, Paolo

PY - 1996/12

Y1 - 1996/12

N2 - An open-label randomized pilot study was conducted to evaluate the efficacy and acceptability of 6 months treatment with leuprolide in a 3-monthly versus a monthly i.m. depot injection for the relief of chronic pelvic pain in women with endometriosis. A total of 30 women aged 18-38 years were allocated to the 3-monthly depot arm (n = 15) or to the monthly depot arm (n = 15) after laparoscopic diagnosis of pelvic endometriosis. Mean (SD) deep dyspareunia scores according to a 0-3 point verbal rating scale decreased from 1.8 (0.9) at baseline to 1.3 (0.7) at the end of treatment in the 3-monthly depot group and from 2.1 (1.2) to 1.3 (0.7) in the monthly depot group. Corresponding values in non-menstrual pain scores fell from 2.1 (0.6) to 1.1 (0.3), and from 2.1 (0.8) to 1.2 (0.4) respectively, without statistically significant differences between the groups. Serum luteinizing hormone (LH) and 17β-oestradiol concentrations were significantly suppressed at 12 and 24 weeks compared with baseline values, without differences between the groups. The monthly depot caused a slightly more marked inhibition of serum follicle stimulating hormone (FSH) levels with respect to the 3-monthly preparation. Mean (SD) endometriosis scores at baseline and at 6 month follow-up laparoscopy were respectively 32.8 (25.1) and 12.2 (9.3) in the 3-monthly depot group and 29.0 (22.7) acid 13.1 (15.3) in the monthly depot group (paired t-test, P <0.05). Mean percentage decrease in lumbar spine bone mineral density was 5.2% in the former and 4.9% in the latter subjects. In the 3-monthly depot group, 13 women graded the tolerability of their treatment schedule as 'good' compared with seven in the monthly depot group (χ 2 = 5.40, P = 0.02).

AB - An open-label randomized pilot study was conducted to evaluate the efficacy and acceptability of 6 months treatment with leuprolide in a 3-monthly versus a monthly i.m. depot injection for the relief of chronic pelvic pain in women with endometriosis. A total of 30 women aged 18-38 years were allocated to the 3-monthly depot arm (n = 15) or to the monthly depot arm (n = 15) after laparoscopic diagnosis of pelvic endometriosis. Mean (SD) deep dyspareunia scores according to a 0-3 point verbal rating scale decreased from 1.8 (0.9) at baseline to 1.3 (0.7) at the end of treatment in the 3-monthly depot group and from 2.1 (1.2) to 1.3 (0.7) in the monthly depot group. Corresponding values in non-menstrual pain scores fell from 2.1 (0.6) to 1.1 (0.3), and from 2.1 (0.8) to 1.2 (0.4) respectively, without statistically significant differences between the groups. Serum luteinizing hormone (LH) and 17β-oestradiol concentrations were significantly suppressed at 12 and 24 weeks compared with baseline values, without differences between the groups. The monthly depot caused a slightly more marked inhibition of serum follicle stimulating hormone (FSH) levels with respect to the 3-monthly preparation. Mean (SD) endometriosis scores at baseline and at 6 month follow-up laparoscopy were respectively 32.8 (25.1) and 12.2 (9.3) in the 3-monthly depot group and 29.0 (22.7) acid 13.1 (15.3) in the monthly depot group (paired t-test, P <0.05). Mean percentage decrease in lumbar spine bone mineral density was 5.2% in the former and 4.9% in the latter subjects. In the 3-monthly depot group, 13 women graded the tolerability of their treatment schedule as 'good' compared with seven in the monthly depot group (χ 2 = 5.40, P = 0.02).

KW - Endometriosis

KW - Gonadotrophin releasing hormone agonists

KW - Pelvic pain

UR - http://www.scopus.com/inward/record.url?scp=0030479668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030479668&partnerID=8YFLogxK

M3 - Article

C2 - 9021380

AN - SCOPUS:0030479668

VL - 11

SP - 2732

EP - 2735

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 12

ER -